- Home
- BFRI vs VYNE Comparison
BFRI vs VYNE Comparison
Compare BFRI & VYNE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BFRI
- VYNE
- Stock Information
- Founded
- BFRI 1997
- VYNE 2003
- Country
- BFRI United States
- VYNE United States
- Employees
- BFRI N/A
- VYNE N/A
- Industry
- BFRI Biotechnology: Pharmaceutical Preparations
- VYNE Biotechnology: Pharmaceutical Preparations
- Sector
- BFRI Health Care
- VYNE Health Care
- Exchange
- BFRI Nasdaq
- VYNE Nasdaq
- Market Cap
- BFRI 11.1M
- VYNE 9.6M
- IPO Year
- BFRI 2021
- VYNE 2018
- Fundamental
- Price
- BFRI $0.88
- VYNE $0.38
- Analyst Decision
- BFRI Strong Buy
- VYNE Buy
- Analyst Count
- BFRI 1
- VYNE 2
- Target Price
- BFRI $2.75
- VYNE $8.00
- AVG Volume (30 Days)
- BFRI 201.2K
- VYNE 1.7M
- Earning Date
- BFRI 11-12-2025
- VYNE 11-06-2025
- Dividend Yield
- BFRI N/A
- VYNE N/A
- EPS Growth
- BFRI N/A
- VYNE N/A
- EPS
- BFRI N/A
- VYNE N/A
- Revenue
- BFRI $37,164,000.00
- VYNE $524,000.00
- Revenue This Year
- BFRI $9.70
- VYNE N/A
- Revenue Next Year
- BFRI $12.58
- VYNE N/A
- P/E Ratio
- BFRI N/A
- VYNE N/A
- Revenue Growth
- BFRI 5.11
- VYNE 6.29
- 52 Week Low
- BFRI $0.54
- VYNE $0.28
- 52 Week High
- BFRI $1.87
- VYNE $4.30
- Technical
- Relative Strength Index (RSI)
- BFRI 37.83
- VYNE 55.78
- Support Level
- BFRI $0.80
- VYNE $0.35
- Resistance Level
- BFRI $1.13
- VYNE $0.38
- Average True Range (ATR)
- BFRI 0.10
- VYNE 0.03
- MACD
- BFRI -0.03
- VYNE 0.00
- Stochastic Oscillator
- BFRI 16.95
- VYNE 88.42
About BFRI Biofrontera Inc.
Biofrontera Inc is a United States-based biopharmaceutical company commercializing a portfolio of pharmaceutical products for the treatment of dermatological conditions with a focus on photodynamic therapy. The Company's licensed products, which include Ameluz as well as the BF-RhodoLED and RhodoLED XL lamps (together, the RhodoLED Lamps), are used for the treatment of actinic keratoses (AKs), which are pre-cancerous skin lesions.
About VYNE VYNE Therapeutics Inc.
VYNE Therapeutics Inc is a biopharmaceutical company focused on developing proprietary, innovative and differentiated therapies for the treatment of immuno-inflammatory conditions. Its advanced product candidate is FMX114, which is being evaluated for the potential treatment of mild-to-moderate AD (atopic dermatitis). The company is also in the pre-clinical stages of developing products containing BET (Bromodomain and Extra-Terminal Domain) inhibitor compounds. Its products include AMZEEQ, ZILXI, and FCD105.